Squire Patton Boggs has advised the shareholders of Dolon, the healthcare pricing and market access consultancy, on the company’s acquisition by Prescient Healthcare Group. The transaction is supported by Prescient’s existing investor Bridgepoint, which partnered with the company in 2021 via Bridgepoint Development Capital. Financial details of the transaction were not disclosed.
The Squire Patton Boggs team was led by Corporate partner Joe Abbott in London supported by Corporate associates Isabelle Sadler and Summer Prior.
Prescient is a science and insight-led development and commercialization partner that helps pharma and biotech companies unlock the full value of their assets, through seamless integration of deep scientific acumen, multi-dimensional insights, functional area expertise and sharp strategic thinking.
Dolon is a global strategic pricing and market access consultancy specialising in rare diseases and oncology. Headquartered in London, with teams across the US and Europe, Dolon supports biopharma companies address complex pricing, reimbursement and access challenges internationally.
The transaction represents the next step in Prescient’s expansion, strengthening its ability to support global biopharma companies navigating increasingly complex and interconnected clinical, commercial and market access environments. Dolon will retain its specialist focus, joining as a dedicated Value, Pricing and Access practice working alongside Prescient’s established teams.
